Medicines Formulary

Medicines A–Z

E

Drug name	NICE TAs	Comments
Enzalutamide capsules	TA316 - Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen TA712 - Enzalutamide for treating hormone-sensitive metastatic prostate cancer	For hospital use only
Eosin solution 2% w/v		Unlicensed special
Epaderm ointment
Ephedrine injection		Hospital use only
Ephedrine nose drops 0.5% and 1% drops		Short term use only
Epimax®
Epirubicin injection		For hospital use only
Epirubilin solution for injection	TA250 - Eribulin for the treatment of locally advanced or metastatic breast cancer TA423 - Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Eplerenone tablets
Epoetin beta syringe (Neorecormon)	TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	NHSE commissioned renal dialysis. CCG Commissioned for use in cancer - NICE TA323.

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.